Semaglutide research monograph — GLP-1 pharmacology and the STEP/SELECT trial record

Semaglutide is the most extensively studied compound in the GLP-1 class, and the
human evidence base for it is unusually large. This monograph summarizes the
pharmacology and the trial record.

Chemical identity & structure.
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist — a synthetic
analog of the human incretin hormone GLP-1. Its structure is engineered for
durability: an amino-acid substitution at position 8 (alpha-aminoisobutyric acid,
"Aib") blocks degradation by the enzyme DPP-4, and a C18 fatty-diacid chain
attached via a linker promotes reversible binding to albumin in the bloodstream.
Together these modifications extend the half-life to roughly 7 days, which is
what makes once-weekly research dosing possible.

Mechanism of action.
Semaglutide activates the GLP-1 receptor. The downstream effects relevant to
metabolic research are: glucose-dependent stimulation of insulin secretion,
suppression of glucagon, slowing of gastric emptying, and central effects on
appetite and satiety signaling via GLP-1 receptors in the hypothalamus and
hindbrain. The "glucose-dependent" qualifier matters — insulin release is
amplified only when glucose is elevated, which is relevant to the class's
hypoglycemia profile.

Key research findings.
In the SUSTAIN program (type 2 diabetes), semaglutide improved glycemic control
and produced weight loss as a secondary outcome. The STEP program studied
semaglutide specifically for weight management at higher doses and documented
substantial sustained weight loss over 68 weeks. The SELECT trial reported a
reduction in major adverse cardiovascular events in a population with
established cardiovascular disease and overweight/obesity. The FLOW trial
examined kidney outcomes.

The research / citation base.
Semaglutide is approved by the FDA and other regulators for type 2 diabetes
(Ozempic, Rybelsus) and for chronic weight management (Wegovy). The trial
program (SUSTAIN, PIONEER, STEP, SELECT, FLOW) is large and published in major
peer-reviewed journals. This is one of the best-evidenced compounds in the
entire peptide space.

Research protocols in the literature.
Published trials use once-weekly subcutaneous administration with a gradual
dose-escalation schedule over several weeks, a design intended to limit
gastrointestinal side effects. An oral formulation (with an absorption enhancer)
also exists. Research-grade lyophilized material requires reconstitution and
cold-chain handling.

Quality & sourcing notes.
Counterfeit and underdosed semaglutide is a documented, serious problem in the
research-grade supply chain. A credible COA should confirm identity by mass
spectrometry and purity by HPLC, and should be batch-specific. Peptide mass for
semaglutide is approximately 4114 Da — a COA reporting a materially different
mass is a red flag.

*Research-use note: This is an educational summary of published research.
Semaglutide is a prescription drug; this monograph is research context only and
is not medical advice.*